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Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an ever-
increasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to
play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essen-
tial for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is effi-
cacious against murine malaria.
Malaria is a major cause of morbidity and mortality world-wide, with as many as 1 million deaths each year (3). While
four Plasmodium species commonly infect humans, malaria
caused by Plasmodium falciparum is responsible for most deaths,
particularly in children under the age of 5 and pregnant women (2,
24). Both prevention and treatment of P. falciparum malaria are
under threat because of the spread of drug-resistant parasites. Re-
sistance to chloroquine is now considered almost universal (36),
while the efficacy of affordable antimalarial drugs, such as sulfa-
doxine-pyrimethamine, the major drug used for intermittent pre-
ventative therapy, is declining (19, 22). Artemisinin and its deriv-
atives may be our last line of drug defense, although recent reports
have indicated signs of reduced effectiveness of artemisinin com-
bination therapies (ACTs) (23, 28). For the development of the
next generation of antimalarial agents, new targets and pathways
susceptible to interruption by chemotherapy need to be identified.
The asexual intraerythrocytic stages of Plasmodium develop-
ment are responsible for the clinical symptoms attributable to
malaria, and most antimalarial drugs target these stages of the
parasite’s life cycle (15, 30). Many laboratories have focused on the
hydrolytic process of hemoglobin (Hb) digestion within the par-
asite’s specialized digestive vacuole as a target for drug discovery
(4, 7, 16, 18, 32). During the asexual development phase, malaria
parasites degrade 65 to 75% of their host cell’s Hb, a process that
ultimately results in the release of amino acids that are used by the
parasite for protein anabolism (29) and the maintenance of os-
motic pressure within the infected erythrocyte (14). Two metal-
loaminopeptidase enzymes, the P. falciparum M1 alanine amino-
peptidase (PfM1AAP) and the P. falciparum M17 leucine
aminopeptidase (PfM17LAP), may be critical in the terminal
stages of Hb degradation and the release of free amino acids (6,
21). We have shown that inhibitors of these aminopeptidases,
such as the natural Phe-Leu dipeptide analog bestatin, derived
from the fungus Streptomyces olivoretticuli, and several synthetic
phosphinate dipeptide analogs, can kill P. falciparum parasites in
culture. These compounds are also effective against the rodent
malaria parasite Plasmodium chabaudi chabaudi in vivo when ad-
ministered intraperitoneally (i.p.) (32, 33). We have also recently
reported the production and characterization of functionally ac-
tive recombinant P. falciparum M1 alanine aminopeptidase
(rPfM1AAP) and M17 leucine aminopeptidase (rPfM17LAP) and
their crystal structures complexed to the aminopeptidase inhibi-
tors bestatin and the phosphinate hPheP[CH2]Phe (20, 21, 34).
The aminopeptidase inhibitor CHR-2863 {(S)-[(R)-2-((S)-hy-
droxycarbamoyl-methoxy-methyl)-4-methyl-pentanoylamino]-
phenyl-acetic acid cyclopentyl ester} (Fig. 1A) is a hydroxam-
ate-containing ester compound closely related to CHR-2797
(tosedostat), a potent inhibitor of a number of intracellular mam-
malian aminopeptidases. While some hydroxamate-containing
compounds are known to be promiscuous and inhibit various
families of metalloenzymes, such as histone deacetylases and ma-
trix metalloproteinases, this is not the case for these aminopepti-
dase inhibitors (13). Tosedostat has been shown to exert antipro-
liferative effects against a range of human tumor cell lines in vitro
and in vivo and has completed phase I/II trials for the treatment of
acute myeloid leukemia (AML) and myelodysplasia (13). Both
CHR-2863 and CHR-2797 are converted into pharmacologically
active charged acid products inside cells by the action of cytoplas-
mic carboxyesterases (23). In the case of CHR-2863, the ester
is converted into (S)-[(R)-2-((S)-hydroxycarbamoyl-methoxy-
methyl)-4-methyl-pentanoylamino]-phenyl-acetic-acid (CHR-
6768) (Fig. 1A). Here, we show that CHR-2863 and CHR-6768 kill
P. falciparum malaria parasites in culture and that oral adminis-
tration of the former is efficacious against rodent malaria in vivo.
MATERIALS AND METHODS
Compounds. The compounds CHR-2863 and CHR-6769 {(S)-[(R)-2-
((S)-hydroxycarbamoyl-methoxy-methyl)-4-methyl-pentanoylamino]-
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phenyl-acetic-acid} were supplied by Chroma Therapeutics Ltd., Abing-
don, United Kingdom, and synthesized as previously described (13).
Bestatin was purchased from Sigma.
Parasites and parasite extracts. The P. falciparum chloroquine-sensi-
tive clone 3D7, derived from P. falciparum isolate NF54, and the multi-
drug-resistant clone K1 were used in all in vitro drug assays. The parasites
were cultured as previously described (35). Soluble malaria extracts were
prepared as previously reported (34), and 5 g total protein was used in
each assay. The murine malaria species used in in vivo assays was the
nonlethal Plasmodium chabaudi chabaudi obtained from frozen stocks
and passaged once in female C57BL/6 mice.
Recombinant PfM1AAP and PfM17LAP. rPfM1AAP and rPfM17LAP
were prepared and purified in our laboratory as previously described
(21, 34).
Enzyme inhibitor constants. Enzyme assays employed the fluoro-
genic peptide substrate H-leucine-7-amido-4-methylcoumarin (H-Leu-
NHMec), a substrate that is cleaved efficiently by both PfM1AAP and
PfM17LAP. Initial rates were obtained at 37°C using a range of substrate
(H-Leu-NHMec) concentrations spanning the enzyme’s Km (0.2 to 1,000
M) and at fixed enzyme concentrations in 50 mM Tris-HCl, pH 7.5.
Progress curves were monitored until a final steady-state velocity, Vs, was
reached. Ki values were determined from Dixon plots of 1/Vs versus the
inhibitor concentration when [S] is much less than Km, as described pre-
viously (20, 21, 34).
In silico docking of inhibitors. Molecular analysis and docking stud-
ies were carried out using the Schrodinger 2011 suite of modeling tools.
Docking grids were prepared, using Glide (Fig. 2A) (5, 10), from solid-
state structures of unliganded proteins deposited in the RCSB Protein
Data Bank (PDB) (http://www.pdb.org) (rPfM1AAP from PDB code
3EBG; rPfM17LAP from PDB code 3KQZ) after using the Schrodinger
Protein Preparation Tool (Schrodinger Suite 2011 Protein Preparation
Wizard) and an Impref minimization to a converged heavy-atom root
mean square (RMS) of 0.3 Å. Bestatin and CHR2863 ligands were pre-
pared using LigPrep (version 2.5; Schrodinger) incorporating Epik metal
states (8, 26, 31) at pH 7. Docking runs were carried out using the XP
mode of the Glide module.
Parasite growth and sensitivity to inhibitors. Serial dilutions of each
inhibitor were prepared in culture media and added, with [3H]hypoxan-
thine (0.5 Ci/well), to asynchronous cultures at a 0.5% parasitemia and
2% hematocrit. The amount of [3H]hypoxanthine incorporated into par-
asites was measured after an incubation of 48 h. The concentrations of
inhibitor required to prevent incorporation by 50% (IC50s) were deter-
mined by nonlinear regression analysis (SigmaPlot). Each assay was per-
formed in triplicate on two separate occasions, and the data were pooled
and are presented as mean  standard deviation (SD).
Morphological assessment of inhibitors. Asynchronous cultures of
P. falciparum 3D7 were exposed to CHR-2863 (5 M). Morphological
changes were assessed over 24 and 48 h and compared to those of no-drug
FIG 1 Structure, enzyme kinetics, and binding mode of the novel aminopeptidase inhibitor CHR-2863. (A) CHR-2863 and CHR-6768. (B) Ki values and XP
dock scores of CHR-2863 and CHR-6768 compared to those of bestatin when assessed against rPfM1AAP and rPfM17LAP. (C) Inhibition curves of aminopep-
tidase activity in malaria extracts. The substrate (H-Leu-NHMec) was maintained at 25 M, while the inhibitor compounds were varied. Soluble malaria extract
was prepared as previously reported (21), and 5 g total proteins was used in each assay. (D) Schematic representations of metal-ligand interaction diagrams for
rPfM1AAP and rPfM17LAP illustrating the different cavity binding orientations observed in the solid state for bestatin and the proposed structures for CHR 2863
based on docking analysis. (a) rPfM1AAP and bestatin (derived from X ray data; PDB code 3EBH); (b) rPfM17LAP and bestatin X-ray (derived from PDB code
3KR4); (c) rPfM1AAP docked with CHR-2863; (d) rPfM17LAP docked with CHR-2863.
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controls, together with the well-characterized inhibitor E64 (Fig. 3A).
Giemsa-stained blood smears were examined by light microscopy
(1,000 magnification).
In vivo suppression test. In vivo activity was assessed using a modified
4-day suppression test (27) employing the P. c. chabaudi murine malaria
model in C57/BL6J mice (Fig. 3B). Five groups of mice were used in these
experiments, including (i) a no-drug vehicle control group; (ii) a group
given one daily dose of 100 mg/kg of body weight of CHR-2863 on days 1
and 2, followed by one daily dose of 50 mg/kg on days 3 and 4; (iii) a group
given one daily dose of 50 mg/kg of CHR-2863 on days 1 to 4; (iv) a group
given one daily dose of 25 mg/kg of CHR-2863 on days 1 to 4; and (v) a
group given a daily dose of 14 mg/kg malarone (atovaquone at 10 mg/kg
plus proguanil at 4 mg/kg) on days 1 to 3. Each mouse received 1  105 P.
c. chabaudi parasites intravenously on day 0, and all compounds, includ-
ing the vehicle control, were administered by oral gavage in a total volume
of 200 l. Dosing of the animals commenced 24 h after inoculation of
parasites and was repeated at 24-h intervals. All procedures used in the
assay were ratified by the Queensland Institute of Medical Research Ani-
mal Ethics Committee.
RESULTS
CHR-2863 and CHR-6768 are potent inhibitors of malaria
aminopeptidases. Data describing the activities of CHR-2863
(Fig. 1A, ester), CHR-6768 (Fig. 1B, acid), and bestatin against
recombinant PfM1AAP and PfM17LAP demonstrate that CHR-
2863 is a potent inhibitor of both aminopeptidases (Fig. 1B); it was
almost twice as potent (Ki  1.4 M) as the acid derivative CHR-
6768 (Ki  2.4 M) and about equally as potent as bestatin (Ki 
1.6 M) against the rPfM1AAP enzyme. While both CHR-2863
and CHR-6768 showed far greater potency (20- to 100-fold)
against rPfM17LAP than rPfM1AAP, the acid CHR-6768 (Ki 
0.025 M) exhibited a 3-fold greater inhibition constant than
CHR-2863 (Ki  0.075 M). CHR-2863 and CHR-6768 were 8-
and 24-fold more potent, respectively, against rPfM17LAP than
bestatin (Fig. 1B).
Using the peptide H-Leu-NHMec as a substrate, we assessed
the relative potencies of CHR-2863, CHR-6768, and bestatin
against the aminopeptidase activity in freeze-thaw soluble extracts
of P. falciparum parasites (34). The inhibition curves presented
(Fig. 1C) were performed with 25 M substrate. Both CH-2863
and CHR-6768 are more potent inhibitors of aminopeptidase ac-
tivity in malaria extracts than bestatin. These results are consistent
with data generated with purified recombinant enzymes (Fig.
1B). Since the precise concentrations of native PfM1AAP and
PfM17LAP in these extracts are not known, we determined the
concentrations of inhibitor that inhibited 50% of the total enzyme
activity in these samples: 75 nM, 78 nM, and 300 nM for the
CHR-2863, CHR-6768, and bestatin, respectively.
In silico modeling identifies a different binding modality of
CHR-2863 than of bestatin. Analysis of solid-state data within the
protein structural data bank (http://www.rcsb.org) on several hy-
droxamic acid-based structures similar to CHR-2863 that bind to
zinc metalloproteins suggested that compounds of this type che-
late the metal ion via the terminal hydroxamic acid regions of the
molecules. In conjunction with the PDB analysis outlined above,
we used computer simulation and docking techniques to formu-
late a molecular interpretation of how CHR-2863 inhibits
rPfM1AAP and rPfM17LAP. This analysis was implemented by
modeling the ligand structure into the unliganded active site of the
structures of the relevant malaria enzymes previously determined
by us (20, 21). These analyses predicted that compounds such as
CHR-2863 bind strongly to the active sites of these enzymes and
also that they may adopt orientations within the binding cavities
of rPfM1AAP and rPfM17LAP different from that reported by us
for bestatin (20, 21). In both the rPfM1AAP and rPfM17LAP pro-
teins, CHR-2863 interacts via a monoanionic binding mode that
exists between the terminal hydroxamic region of the chelator and
the metal ion(s) of the protein. This is in contrast to the bestatin
mode of binding observed in the solid state of both rPfM1AAP
and rPfM17LAP, in which the metal ion(s) of the protein interacts
with the center region of the bestatin proximal to the hydroxyl
methylene group (Fig. 1D). Changes are also observed in the over-
all orientation of the molecules within the binding cavity distal to
the metal center. For example, in rPfM1AAP, both the docking
FIG 2 (A) The calculated locations of CHR-2863 and bestatin within the binding site of rPfM1AAP obtained by molecular docking studies using Glide.
CHR-2863 (blue) is predicted to occupy a region of the substrate-binding cavity different from that observed in both the X-ray-derived solid-state structure and
our docking analysis for bestatin (green). Oxygen atoms are highlighted in red, the zinc ion is highlighted in orange/brown and the proximal hydrophobic
residues are shown inset into a semitransparent Van der Waals (VDW) molecular surface. (B) The calculated locations of CHR-2863 and bestatin within the
binding site of rPfM17LAP obtained by molecular docking studies using Glide. Analysis revealed that the phenyl group of CHR-2863 and the isopropyl group of
bestatin occupy the same hydrophobic region of the rPfM17LAP protein, while the phenyl group of CHR- 2863 projects into a region proximal to Tyr493 and
Ala388. Oxygen atoms are highlighted in red, the zinc ions are highlighted in yellow, and the proximal residues are shown inset into a semitransparent VDW
molecular surface.
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simulation and solid-state X-ray data (obtained from PDB code
3EBH) reveal that the phenyl ring of bestatin is situated within a
hydrophobic cavity formed by amino acid residues Tyr575, Ala320,
Gln317, and Val459. Other bestatin-protein noncovalent contacts
correlate well with that observed in the solid-state structure, al-
though in the simulation, the bestatin amide NH-C bond is ro-
tated by 180° to that observed in the X-ray data. In contrast, the
CHR-2863 simulation locates the bulk of the molecule in a region
of the protein different from that occupied by bestatin, so that the
hydrophobic phenyl group of CHR-2863 is located in a hydropho-
bic region described by Val550, Thr576, and Thr577. This could be
attributable to the increased molecular volume of CHR-2863 over
bestatin (370 Å3 versus 310 Å3) (Fig. 2A).
Differences were also noted between CHR-2863 and bestatin in
the rPfM17LAP system. In this data set, the docked bestatin mol-
ecule once again occupied a position within the protein cavity
similar to that observed in the bestatin-liganded solid-state struc-
ture (obtained from PDB code 3KR4). For example, the phenyl
region of bestatin is located in a hydrophobic area bounded by
Leu492, Ala577, Phe398, and Met396 in both the simulation and the
X-ray solid-state structure. Interestingly, the simulation again ro-
tated the bestatin amide NH-C bond 180° to that observed in the
X-ray data. While the larger CHR-2863 molecule was slightly re-
moved to the region occupied by bestatin, it was much less pro-
nounced than in the rPfM1AAP system. Further analysis revealed
that the hydrophobic phenyl group of CHR-2863 and the isopro-
pyl group of bestatin occupy the same hydrophobic region of the
rPfM17LAP protein while the phenyl group of CHR-2863 projects
into an region adjacent to that normally occupied by bestatin,
proximal to Tyr493 and Ala388 (Fig. 2B).
CHR-2863 is a more potent in vitro inhibitor of P. falcipa-
rum than bestatin. We investigated the potential antimalarial ac-
tivity of CHR-2863 and the corresponding acid CHR-6768. This
was first examined in vitro against P. falciparum 3D7 using
FIG 3 (A) Morphological changes in P. falciparum parasites seen over a 48-h period when treated with 5 M CHR-2863 compared to an untreated control and
a known cysteine protease inhibitor, E64. (B) Mice infected with P. c. chabaudi parasites were dosed by oral gavage with a range of concentrations of CHR-2863.
Five groups of mice were used: (i) a no-drug vehicle control group, (ii) a group given one daily dose of 100 mg/kg of CHR-2863 on days 1 and 2 followed by one
daily dose of 50 mg/kg on days 3 and 4, (iii) a group given one daily dose of 50 mg/kg of CHR-2863 on days 1 to 4, (iv) a group given one daily dose of 25 mg/kg
of CHR-2863 on days 1 to 4, and (v) a group given a daily dose of 14 mg/kg malarone (atovaquone at 10 mg/kg plus proguanil at 4 mg/kg) on days 1 to 3. Each
mouse received 1  105 P. c. chabaudi parasites intravenously on day 0, and all compounds, including the vehicle control, were administered by oral gavage in
a total volume of 200 l. Dosing of the animals commenced 24 h after inoculation of parasites and was repeated at 24-h intervals. Peak parasitemia corresponds
to the percentage of parasitized red blood cells quantified from Giemsa-stained thin films. The doses on the x axis correspond to the amount of CHR-2863 given
per day over 4 days in mg/kg. A black horizontal line indicates the mean parasitemia of each of the test and control groups. **, P  0.01; ***, P  0.001.
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[3H]hypoxathanine incorporation as a measure of parasite
growth, In these assays, bestatin exhibited an IC50 of 5 M, within
the range we have previously reported (32). The in vitro antima-
larial potency of the CHR-2863 ester (IC50, 370 nM) was 5-fold
greater than that of the acid CHR-6768 (IC50, 2 M). A similar
antimalarial potency (IC50, 376 nM) was obtained when the CHR-
2863 ester was tested against the P. falciparum multidrug-resistant
clone K1.
CHR-2863 induces vacuolization in P. falciparum parasites.
Analysis of parasite morphology after treatment with CHR-2863
demonstrated that, similar to bestatin, CHR-2863 induces a slow-
growth phenotype with some vacuolization. In contrast, the well-
characterized cysteine protease inhibitor E64, which is believed to
specifically target cysteine proteases (falcipains) within the P. fal-
ciparum digestive vacuole, caused significant swelling of this or-
ganelle (Fig. 2A). Whether the effect of CHR-2863 was due to
inhibition of both PfM17LAP and PfM1AAP or of one specific
enzyme cannot be realistically determined from these observa-
tions, since the compound inhibits both enzymes.
CHR-2863 shows antimalarial activity and is orally bioavail-
able. The clinical significance of the antimalarial activity demon-
strated by CHR-2863 was examined in vivo. Using a modified
4-day suppression test, we assessed the treatment of mice infected
with the murine malaria species P. c. chabaudi. Treatment with
CHR-2863 significantly reduced the peak parasitemia in all
groups compared to the vehicle control group, with higher doses
showing an increased effect on parasite growth (Fig. 2B).
DISCUSSION
To support its rapid growth in vivo, P. falciparum must acquire
nutrients from the host cell and the extracellular environment.
Digestion of host cell hemoglobin is essential for the parasite to
acquire sufficient amino acids to facilitate parasite anabolism. We
and others have previously shown that the two P. falciparum
aminopeptidases PfM1AAP and PfM17LAP are essential to this
process, and while there is some overlapping substrate specificity
between the enzymes, they both appear to be essential for parasite
viability, indicating that they may play different roles in the life
cycle of the parasite (1, 11).
CHR-2863 is a hydroxamate-containing ester compound
closely related to CHR-2797 (tosedostat), itself a potent inhibitor
of a number of intracellular mammalian aminopeptidases. In or-
der to assess whether CHR-2863 could inhibit P. falciparum
aminopeptidases, we determined the inhibitor constants of the
compound and its acid derivative against recombinant PfM1AAP
and PfM17LAP. In both cases, these compounds showed signifi-
cantly increased activity against PfM17LAP compared to bestatin,
with Kis in the low nanomolar range with an almost 10-fold in-
crease in inhibitory activity. The figures for the Glide dock scores
suggested that CHR-2863 would be an inhibitor comparable to, if
not better than, bestatin, and the values correlated well with the
observed inhibitory data (Fig. 1B). This increase in inhibitory ac-
tivity, however, was not repeated when the two compounds were
assessed against rPfM1AAP. In this case, both inhibitors were in
the range observed for bestatin, the low M range. While the
substrate specificity of PfM1AAP is much broader than that of
PfM17LAP, most inhibitors of these enzymes appear to target
PfM17LAP preferentially to PfM1AAP, except for a series recently
described by Harbut et al. (11), where they extensively modified
the bestatin scaffold in an attempt to create specific inhibitors for
both enzymes.
We previously reported, using the murine malaria model P.
c. chabaudi, that the aminopeptidase inhibitors bestatin and
hPheP[CH2]Phe exhibited in vivo antimalarial activity and thus
provided proof of concept for aminopeptidases being considered
targets for antimalaria drug development (32). Given the apparent
higher activity of the ester derivative (CHR-2863) than of the acid
(CHR-6768) in an in vitro P. falciparum assay (IC50, 370 nM vs 2
M), we assessed only the antimalarial activity of CHR-2863 in
vivo using the rodent P. c. chabaudi model. A treatment dose of 25
mg/kg given only once a day reduced the parasite burdens in
treated mice significantly compared to controls, and further dose
increments showed a dose-dependent reduction in the parasite
burden in the treated groups (Fig. 2). These data provide further
evidence of the successful use of aminopeptidase inhibitors as an-
timalarial agents by demonstrating for the first time that oral ad-
ministration of CHR-2863 reduces parasite burdens in vivo
(Fig. 2).
Drug resistance is such a major problem for the control and
treatment of malaria that novel targets and lead compounds for
the development of new drugs are in continual demand (25). This
study establishes the possibility that PfM17LAP and PfM1AAP
could become antimalarial drug targets by demonstrating a clear
relationship between the ability of inhibitors to inactivate the en-
zymes and to kill malaria parasites in vitro and in vivo. The com-
pounds CHR-2863 and CHR-6768 are some of the most potent
inhibitors of M17 LAPs reported to date (9, 11). Their potency
makes them attractive lead compounds for the development of
antimalaria therapeutic agents. The present studies show that
CHR-2863 has exhibited in vivo antimalarial activity when dosed
orally at 25 mg/kg once daily. These data demonstrate that it is
now possible to target malaria aminopeptidases by oral adminis-
tration of inhibitors, an important consideration, since bioavail-
ability is a prerequisite for the future progression of antimalaria
drugs into the development pipeline. Previous phase I/II studies
with a similar compound, tosedostat (60 mg to 180 mg for 28
days), have shown that it is one of only a few orally delivered
monotherapy agents that have shown promising activity and good
tolerability in elderly and/or refractory or relapsed AML and my-
elodysplasia patients (17). Bestatin is currently used as a mainte-
nance treatment for patients with acute nonlymphocytic leukemia
who are in complete remission after chemotherapy as a result of
randomized trials for such patients. An oral treatment of 30 mg
daily for 2 years has been shown to be safe in over 2,000 patients,
with only infrequent and mild adverse reactions (hepatic dysfunc-
tion, skin reaction, or gastrointestinal toxicity, including nausea,
vomiting, and anorexia). Thus, there is a precedent for using ami-
nopeptidase inhibitors for disease prevention in humans and ev-
idence that they have few side effects (12). Nonetheless, the toxic-
ity of any new antimalarial drug needs to be investigated fully
prior to human experimentation.
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